Unmet Need Can Trump Anything At US FDA Panels, Even An Ill-Prepared Sponsor

Emmaus was unable to answer several questions about its product and was also missing several pieces of data, but FDA's Oncologic Drugs Advisory Committee didn't criticize the sponsor, and instead praised it for paying attention to the largely neglected sickle cell disease.

More from US FDA Performance Tracker

More from Regulatory Trackers